Anzeige
+++Was passiert, wenn das tatsächlich funktioniert?: Der Ripple-Effekt, über den niemand spricht Der Ripple-Effekt, über den niemand spricht+++
EQS-News

Golden Helix Partners with the Austrian Human Genetics Labs to Drive Advancements in Genomic Medicine 17.03.2026, 13:05 Uhr von EQS News Jetzt kommentieren: 0

EQS-News: Golden Helix, Inc. / Key word(s): Agreement
Golden Helix Partners with the Austrian Human Genetics Labs to Drive Advancements in Genomic Medicine

17.03.2026 / 13:05 CET/CEST
The issuer is solely responsible for the content of this announcement.


BOZEMAN, Mont., March 17, 2026 /PRNewswire/ -- Golden Helix, a global leader in bioinformatics solutions for Next-Generation Sequencing (NGS) and precision medicine, is proud to announce a strategic agreement with the Austrian public medical genetics labs. The agreement aims to enhance the genomic capabilities of multiple laboratories within the country, supporting critical advancements in cancer and hereditary disease diagnostics.

Golden Helix Logo

In a unified effort across Austria's healthcare regions, the six designated Centres for Medical Genetics in Austria are committed to interconnecting their existing Golden Helix's high-quality genomic technologies into harmonized clinical workflows to improve patient outcomes. With a longstanding relationship spanning over a decade, this multi-year agreement solidifies the trust and commitment between Golden Helix and these institutions, driving state-of-the-art patient care in genomic medicine.

Prof. Dr. med. Zschocke, PhD, Chair of the Austrian Society of Human Genetics (ÖGH) and Professor of Human Genetics of the Medical University Innsbruck: "This agreement with Golden Helix ensures optimal access to Golden Helix's state-of-the-art NGS diagnostic capabilities. We will leverage this in routine diagnostics across all labs, as well as part of the key infrastructure of the Human Genome Project here in Austria. In that regard, the ability to run the software as a medical device in DX mode is key to our routine testing efforts. At the same time, we leverage scalable and high-performing software to run research projects on human genomes at a country-wide scale."

Dr. Laccone, Head of the Clinical Section, Institute of Medical Genetics, at the Medical University of Vienna, said: "We have been working with Golden Helix for over a decade. It is my distinct pleasure to see the relationship grow over all these years. We are excited to enter a new era of human diagnostics that includes also long-read sequencing besides our well-established tests based on short-read technology."

Andreas Scherer, PhD, President & CEO of Golden Helix, expressed his gratitude for the collaboration: "We are humbled by this incredible commitment to Golden Helix by entering into the partnership with the Austrian Medical Genetics Labs. We have over a decade of experience working with labs in that region. We are delighted to take our collaborative efforts to deliver clinical diagnostics and personalized care to the next level."

Golden Helix's software solutions are trusted by institutions worldwide, from clinical labs to research organizations, for their ability to streamline genomic data analysis and support scalable, high-quality workflows. This collaboration further underscores Golden Helix's leadership in empowering healthcare providers with tools to advance precision medicine globally.

About the Austrian Centres of Medical Genetics
Austria's public Medical Genetics system is anchored by six institutions at the Medical Universities Vienna, Innsbruck and Graz, the University Hospitals in Linz and Salzburg, Ordensklinikum Linz, and the Center for Medical Genetics at Hanusch Hospital Vienna that collaborate to support high-quality healthcare and precision medicine. These centers focus on collecting and organizing data from genetic diagnostics, integrating genome analysis and counseling into standard medical care, and contributing directly to Austria's public healthcare system. Their coordinated efforts strengthen collaboration nationwide, support European reference networks for rare diseases, and guide the development of a medically annotated variant database to improve clinical decision-making. Together, the participating centres form a unified network that advances genomic research, improves patient outcomes, and supports long-term public health in Austria.

About Golden Helix
Golden Helix has delivered trusted bioinformatics solutions for over 25 years to hospitals, testing laboratories, research institutions, and national genome programs around the world. With powerful tools for tertiary analysis and genomic warehousing, Golden Helix empowers customers to uncover disease-causing mutations, personalize treatment decisions, and empower Precision Medicine in rare disease diagnostics, oncology and pharmacogenetics.

Persephone Fossi
Marketing and Sales Associate
Golden Helix, Inc
(406) 999-0169
fossi@goldenhelix.com

Logo - https://mma.prnewswire.com/media/1227873/Golden_Helix_Logo.jpg

Cision View original content:https://www.prnewswire.com/de/pressemitteilungen/golden-helix-partners-with-the-austrian-human-genetics-labs-to-drive-advancements-in-genomic-medicine-302715388.html

rt.gif?NewsItemId=EN11126&Transmission_Id=202603170800PR_NEWS_EURO_ND__EN11126&DateId=20260317


17.03.2026 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
View original content: EQS News


2292878  17.03.2026 CET/CEST

Kommentare (0) ... diskutiere mit.
Werbung

Handeln Sie Aktien bei SMARTBROKER+ für 0 Euro!* Profitieren Sie von kostenloser Depotführung, Zugriff auf 29 deutsche und internationale Börsenplätze und unschlagbar günstigen Konditionen – alles in einer innovativen, brandneuen App. Jetzt zu SMARTBROKER+ wechseln und durchstarten!

*Ab 500 EUR Ordervolumen über gettex. Zzgl. marktüblicher Spreads und Zuwendungen.

k.A. k.A. k.A. k.A.
k.A. k.A. k.A. k.A.
k.A. k.A. k.A. k.A.
Schreib den ersten Kommentar!

Dis­clai­mer: Die hier an­ge­bo­te­nen Bei­trä­ge die­nen aus­schließ­lich der In­for­ma­t­ion und stel­len kei­ne Kauf- bzw. Ver­kaufs­em­pfeh­lung­en dar. Sie sind we­der ex­pli­zit noch im­pli­zit als Zu­sich­er­ung ei­ner be­stim­mt­en Kurs­ent­wick­lung der ge­nan­nt­en Fi­nanz­in­stru­men­te oder als Handl­ungs­auf­for­der­ung zu ver­steh­en. Der Er­werb von Wert­pa­pier­en birgt Ri­si­ken, die zum To­tal­ver­lust des ein­ge­setz­ten Ka­pi­tals füh­ren kön­nen. Die In­for­ma­tion­en er­setz­en kei­ne, auf die in­di­vi­du­el­len Be­dür­fnis­se aus­ge­rich­te­te, fach­kun­di­ge An­la­ge­be­ra­tung. Ei­ne Haf­tung oder Ga­ran­tie für die Ak­tu­ali­tät, Rich­tig­keit, An­ge­mes­sen­heit und Vol­lständ­ig­keit der zur Ver­fü­gung ge­stel­lt­en In­for­ma­tion­en so­wie für Ver­mö­gens­schä­den wird we­der aus­drück­lich noch stil­lschwei­gend über­nom­men. Die Mar­kets In­side Me­dia GmbH hat auf die ver­öf­fent­lich­ten In­hal­te kei­ner­lei Ein­fluss und vor Ver­öf­fent­lich­ung der Bei­trä­ge kei­ne Ken­nt­nis über In­halt und Ge­gen­stand die­ser. Die Ver­öf­fent­lich­ung der na­ment­lich ge­kenn­zeich­net­en Bei­trä­ge er­folgt ei­gen­ver­ant­wort­lich durch Au­tor­en wie z.B. Gast­kom­men­ta­tor­en, Nach­richt­en­ag­en­tur­en, Un­ter­neh­men. In­fol­ge­des­sen kön­nen die In­hal­te der Bei­trä­ge auch nicht von An­la­ge­in­te­res­sen der Mar­kets In­side Me­dia GmbH und/oder sei­nen Mit­ar­bei­tern oder Or­ga­nen be­stim­mt sein. Die Gast­kom­men­ta­tor­en, Nach­rich­ten­ag­en­tur­en, Un­ter­neh­men ge­hör­en nicht der Re­dak­tion der Mar­kets In­side Me­dia GmbH an. Ihre Mei­nung­en spie­geln nicht not­wen­di­ger­wei­se die Mei­nung­en und Auf­fas­sung­en der Mar­kets In­side Me­dia GmbH und de­ren Mit­ar­bei­ter wie­der. Aus­führ­lich­er Dis­clai­mer